Navigation Links
Dyadic International Reports 2011 First Quarter Financial Results
Date:5/5/2011

p and paper and biofuels markets
  • Received four new U.S. patents
  • Completed negotiations and entered into R&D collaboration with Sanofi Pasteur and EnGen Bio for certain vaccine applications of Dyadic's patented C1 technology

  • Financial ResultsTotal revenue for the three months ended March 31, 2011 increased approximately 15% to approximately $2.3 million, as compared to approximately $2.0 million for the three months ended March 31, 2010.  The increase was primarily attributable to research revenue of approximately $491,000 for the three months ended March 31, 2011, as compared to approximately $88,000 for the same period in the prior year, reflecting Dyadic's continued commitment to increasing its revenue-generating research and development projects in addition to internally funded projects.

    Gross profit for the first quarter of 2011 increased approximately 95% to approximately $768,000 from approximately $394,000 in the first quarter of 2010. The increase was due mainly to higher gross margins on product sales, increased research and development activity which generally has higher contribution margins, and further cost controls and operational efficiencies.

    General and administrative expenses for the three months ended March 31, 2011 increased approximately 24% to approximately $1.7 million, as compared to approximately $1.4 million for the same period last year due primarily to increased litigation costs.

    Net loss for the quarter ended March 31, 2011 was approximately $1.5 million, or $(0.05) per basic and diluted share, as compared to a net loss of approximately $1.1 million, or $(0.04) per basic and diluted share for the quarter ended March 31, 2010. In 2010, Dyadic recorded a gain on reduction of accrued stockholder litigation of $410,000, which accounted for the majority of the difference.

    At March 31, 2011, cash and cash equivalents were approximately $3.1 million and working capital was appro
    '/>"/>

    SOURCE Dyadic International, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Two New U.S. Patents Issued to Dyadic International
    2. Dyadic International to Announce 2010 Year-End Financial Results and Hold Conference Call on March 10, 2011
    3. Sixth U.S. Patent Issued to Dyadic International
    4. Dyadic International and EnGen Bio to Present at Rodman & Renshaw Annual Global Investment Conference
    5. Dyadic International Raises Additional $1 Million to Complete $4 Million Convertible Note Offering
    6. Dyadic International Reports 2010 Second Quarter Financial Results
    7. Bacterin International Holdings Launches Third Biologic Scaffold
    8. INC Research to Acquire Kendle International for $15.25 per Share in Cash
    9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Baird Growth Stock Conference
    10. Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at 13th International Myeloma Workshop
    11. International Leaders in Electrophysiology Discuss Improving Atrial Fibrillation Treatment Using Novel Endoscopically Guided Laser Ablation Catheter
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/19/2014)... BETHESDA, Md. , Sept. 19, 2014 ... an initiative to harmonize global post-approval changes protocols. ... level of interest in the topic expressed by industry participants ... workshop, held earlier this month in Washington, ... and EMA were on hand for the workshop. Attendees ...
    (Date:9/19/2014)... Sept. 19, 2014 Kiromic, LLC, a ... Kent Hance , the former chancellor of Texas Tech ... as chancellor in July 2014, after raising $1.2 billion for ... Kent Hance , the most successful chancellor in the ... not only as an investor, but also as our new ...
    (Date:9/19/2014)... Research and Markets has announced the addition of ... Mental Disorder) Market - Forecast to 2023" report to ... the human microbiome market is segmented by application, disease, product, ... to be valued as $294 million in 2019 and is ... forecast period of 2019-2023. The market is driven by growing ...
    Breaking Medicine Technology:PDA Launches Effort to Harmonize Global Post-Approval Changes Protocols 2Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3
    ... ALISO VIEJO, Calif., Nov. 9 Clarient, Inc. (Nasdaq: ... oncologists and the pharmaceutical industry, today announced that it is ... New York City. , The first presentation will be made ... 1:40 pm EST on Tuesday, November 17. The conference will ...
    ... Care Reform Bill , Critical legislation would strengthen ... Nov. 7 Today the United States House ... strengthen Medicare for seniors and end discrimination by insurance companies ... , The Affordable Health Care for America Act ...
    Cached Medicine Technology:Clarient to Present at Upcoming Healthcare Investor Conferences in New York City 2AARP Idaho Key Vote News Alert 2AARP Idaho Key Vote News Alert 3
    (Date:9/19/2014)... structure could help predict how willing you are to take ... University found those with greater volume in a part of ... likely to engage in risky behavior than people with less ... the U.S. National Institute on Aging, involved two groups of ... researchers sought to determine how brain structure influences risk taking ...
    (Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- Although ... key health benefits, most middle-aged and older adults ... type of exercise, according to new research. ... the muscle-strengthening recommendations set by the Department of ... Strength is essential for promoting health and ...
    (Date:9/19/2014)... By Alan Mozes ... (HealthDay News) -- Cancer patients burdened by stress and ... for complications following their operation, a new study suggests. ... "deficit" appeared to have a nearly three times greater ... or good quality of life. "We,ve long known ...
    (Date:9/19/2014)... York, NY (PRWEB) September 19, 2014 ... statin medication caused some patients to develop Type 2 ... litigation now underway in U.S. District Court, District of ... Status Report issued on September 12, 2014, discovery is ... things, the report noted that Pfizer, Inc., the manufacturer ...
    (Date:9/19/2014)... using intact cells to treat and cure disease ... it is hindered by the inability of doctors and ... of these cells in patients without resorting to invasive ... September 17 in the online journal Magnetic Resonance ... San Diego School of Medicine, University of Pittsburgh and ...
    Breaking Medicine News(10 mins):Health News:Brain Structure Might Help Predict Risky Behavior 2Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 3Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:A better way to track emerging cell therapies using MRIs 2
    ... By Jenifer Goodwin HealthDay Reporter , THURSDAY, ... antigen (PSA) levels are rising rapidly over time are of ... be done, a new study indicates. PSA is a ... of PSA can be a marker for prostate cancer, although ...
    ... By Amanda Gardner HealthDay Reporter , THURSDAY, Feb. ... plague will probably remain a scourge of centuries past, isolated ... fact, according to a just-released government report, a American lab ... of plague from a laboratory-acquired infection since 1959 and the ...
    ... , THURSDAY, Feb. 24 (HealthDay News) -- ... risk of cancer due to high radiation doses, and ... radiation exposure, a new study suggests. The researchers ... dialysis also have other health conditions that require them ...
    ... cancer organizations have recommended that men with a rapid rise ... there is no other indication and the PSA is within ... PSA velocityis a poor predictor of prostate cancer, and may ... online February 24 in the Journal of the National ...
    ... link between victimization experiences and substance abuse has been ... Chicago. The correlation is especially prevalent among gays, ... says Tonda Hughes, professor and interim head of health ... is lead author of the study, published in the ...
    ... THURSDAY, Feb. 24 (HealthDay News) -- A mouse heart rapidly ... a day after birth, scientists report. With this discovery, ... be found to help the human heart heal itself. ... but they,re somehow permanently switched off," said Eric Olson, co-senior ...
    Cached Medicine News:Health News:Rapid Rise in PSA Levels a Poor Predictor of Prostate Cancer: Study 2Health News:Rapid Rise in PSA Levels a Poor Predictor of Prostate Cancer: Study 3Health News:Plague Kills U.S. Lab Worker 2Health News:Plague Kills U.S. Lab Worker 3Health News:Many Dialysis Patients at Risk for High Radiation Exposure 2Health News:PSA velocity screening for prostate cancer may lead to unnecessary biopsies 2Health News:Strong link found between victimization, substance abuse 2Health News:Scientists Say Newborn Mice Can Regrow Damaged Hearts 2
    Viscoelastic Cannula, 23 g. Angled. 7 mm angled tip cannula with unique hub that facilitates flow of viscoelastic material. Overall length 23 mm. 5/box....
    Anterior Chamber Needle, 27 g. Angled. 5 mm angled tip. Overall length 20 mm. 5/box....
    Nucleus Hydrodissection Cannula, 25 g. Angled with flattened tip. 7 mm angled shaft with flattened tip for insertion under the capsular flap. Overall length 19 mm. 5/box....
    Hydrodissection / Aspiration Cannula, 25 g. Angled with left hook. 10 mm angled shaft with 2.5 mm left hook tip. Overall length 20 mm. 5/box....
    Medicine Products: